Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.44 |
| ▸ | JAK2 | O60674 | 6/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392477 | 0.86 | JAK2 (0.36) | IRAK4JAK2JAK3JAK1HTR2A | |
| SCHEMBL24392256 | 0.84 | IRAK4 (0.40) | IRAK4EGFRFLT1FLT4KDR | |
| SCHEMBL24391894 | 0.82 | CHRM4 (0.52) | IRAK4JAK2JAK3JAK1CHRM4 | |
| SCHEMBL24391678 | 0.81 | JAK2 (0.35) | JAK2JAK3JAK1CHRM4HTR2A | |
| SCHEMBL24392301 | 0.81 | ACKR3 (0.44) | JAK2JAK3HTR2AHTR2C | |
| SCHEMBL24392244 | 0.81 | ENPP1 (0.47) | IRAK4CHRM4EGFRFLT1FLT4 | |
| SCHEMBL24391941 | 0.80 | JAK2 (0.35) | JAK2JAK3JAK1HTR2AHTR2C | |
| SCHEMBL24391928 | 0.80 | JAK2 (0.36) | JAK2JAK3JAK1CHRM4 | |
| SCHEMBL24391613 | 0.78 | JAK2 (0.34) | JAK2JAK3JAK1HTR2AHTR2C | |
| SCHEMBL24392295 | 0.78 | JAK2 (0.34) | JAK2JAK3JAK1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | IRAK4 3547/4885JAK2 3057/4885JAK3 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.